Franklin Resources
TRDA icon

Franklin Resources’s Entrada Therapeutics TRDA Stock Holding History

Franklin Resources’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,102
Closed -$140K – 3336
2026
Q1 		$140K Buy
+11,102
New +$127K ﹤0.01% 2864
2025
Q2 		– Sell
-16,290
Closed -$147K – 3133
2025
Q1 		$147K Hold
16,290
– – ﹤0.01% 2763
2024
Q4 		$282K Hold
16,290
– – ﹤0.01% 2529
2024
Q3 		$290K Hold
16,290
– – ﹤0.01% 2499
2024
Q2 		$232K Buy
16,290
+1,971
+14% +$28K ﹤0.01% 2522
2024
Q1 		$203K Buy
14,319
+1,113
+8% +$15.7K ﹤0.01% 2589
2023
Q4 		$199K Buy
+13,206
New +$196K ﹤0.01% 2352

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Franklin Resources's TRDA Position: Q2 2026 in Review

Franklin Resources sold out of Entrada Therapeutics (TRDA) in Q2 2026, closing a stake of 11,102 shares — an estimated $140K sold.

Franklin Resources first reported a position in TRDA in Q4 2023 and held it in 7 quarters. The position peaked at $290K in Q3 2024. 129 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • Franklin Resources reported no remaining Entrada Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Franklin Resources sold 11,102 Entrada Therapeutics shares in Q2 2026, an estimated $140K.
  • Franklin Resources first reported a position in Entrada Therapeutics in Q4 2023 and held it in 7 quarters.
  • Franklin Resources's Entrada Therapeutics position peaked at $290K in Q3 2024.
  • 129 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Franklin Resources's 13F filing for Q2 2026, filed 13 Aug 2026.